Key Takeaways
- Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from Federal Reserve Chair Jerome Powell due later in the week.
- Novo Nordisk shares climbed after the Food and Drug Administration approved the drugmaker’s popular Wegovy weight-loss medicine to treat a serious liver disease.
- Dayforce shares surged following reports it’s held talks about a takeover by private equity firm Thoma Bravo.
Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from Federal Reserve Chair Jerome Powell due later in the week.
Dayforce (DAY) was the best-performing stock in the S&P 500 following a report that private equity firm Thoma Bravo is in discussions to acquire the human resources software provider.
U.S.-listed shares of Novo Nordisk (NVO) also advanced after the Food and Drug Administration approved the drugmaker’s popular Wegovy weight-loss medicine to treat a serious liver disease.
First Solar (FSLR) and other solar stocks gained in the wake of new guidance from the Treasury Department on federal tax incentives for clean energy projects. Citi and Jefferies analysts said the release was better than anticipated.
CVS Health (CVS) shares rose following an upgrade from UBS, which pointed to the drugstore and healthcare company’s cost-cutting and improving healthcare benefits division.
EQT (EQT) shares fell as the energy provider was downgraded from Roth Capital Partners on concerns an oversupply of natural gas will send prices down and hurt EQT’s results.
Oil and gold futures slid. The yield on the 10-year Treasury note was little changed. The U.S. dollar gained on the euro, pound, and yen.
TradingView